Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Garcia, J. Alexander, L. Wallentin, D. Wojdyla, L. Thomas, M. Hanna, S. Al‐Khatib, P. Dorian, J. Ansell, P. Commerford, G. Flaker, F. Lanas, D. Vinereanu, D. Xavier, E. Hylek, C. Held, F. Verheugt, C. Granger, R. Lopes (2014)
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.Blood, 124 25
J. Andrade, A. Verma, L. Mitchell, R. Parkash, K. Leblanc, C. Atzema, J. Healey, A. Bell, J. Cairns, S. Connolly, J. Cox, P. Dorian, D. Gladstone, M. Mcmurtry, G. Nair, L. Pilote, J. Sarrazin, M. Sharma, A. Skanes, M. Talajic, T. Tsang, S. Verma, D. Wyse, S. Nattel, L. Macle (2018)
Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
H. Diener, J. Eikelboom, S. Connolly, C. Joyner, R. Hart, G. Lip, M. O’Donnell, S. Hohnloser, G. Hankey, O. Shestakovska, S. Yusuf (2012)
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trialThe Lancet Neurology, 11
Pradaxa 75 mg hard capsules: summary of product characteristics
AJ Camm, P Kirchhof, GY Lip (2010)
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Eur Heart J, 31
G. Lip, F. Andreotti, L. Fauchier, K. Huber, E. Hylek, E. Knight, D. Lane, M. Levi, F. Marín, G. Palareti, P. Kirchhof, Jean-Philippe Collet, A. Rubboli, Daniela Poli, J. Camm (2011)
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 13 5
(2011)
Prevencion de embolismo por FA
J. Healey, J. Eikelboom, J. Douketis, L. Wallentin, J. Oldgren, Sean Yang, E. Themeles, Hein Heidbuchle, Á. Avezum, P. Reilly, S. Connolly, S. Yusuf, M. Ezekowitz (2012)
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized TrialCirculation, 126
S. Hohnloser, J. Oldgren, Sean Yang, L. Wallentin, M. Ezekowitz, P. Reilly, J. Eikelboom, M. Brueckmann, S. Yusuf, S. Connolly (2012)
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 125
M. Wieloch, A. Själander, V. Frykman, M. Rosenqvist, N. Eriksson, P. Svensson (2011)
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.European heart journal, 32 18
Marino Leonardi, J. Bissett (2005)
Prevention of atrial fibrillationCurrent Opinion in Cardiology, 20
A. Rabinstein (2009)
Effect of Clopidogrel Added to Aspirin in Patients with Atrial FibrillationYearbook of Neurology and Neurosurgery, 2009
J. You, D. Singer, P. Howard, D. Lane, M. Eckman, M. Fang, E. Hylek, S. Schulman, A. Go, M. Hughes, F. Spencer, W. Manning, J. Halperin, G. Lip (2012)
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest, 141 2 Suppl
S. Mantha, J. Ansell (2012)
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillationThrombosis and Haemostasis, 108
C. Miller, S. Grandi, A. Shimony, K. Filion, M. Eisenberg (2012)
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.The American journal of cardiology, 110 3
M. Ezekowitz, L. Wallentin, S. Connolly, A. Parekh, M. Chernick, J. Pogue, Timothy Aikens, Sean Yang, P. Reilly, G. Lip, S. Yusuf (2010)
Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial FibrillationCirculation, 122
S. Connolly, J. Eikelboom, C. Joyner, H. Diener, R. Hart, S. Golitsyn, G. Flaker, Á. Avezum, S. Hohnloser, R. Diaz, M. Talajic, Jun Zhu, P. Pais, A. Budaj, A. Parkhomenko, P. Janský, P. Commerford, R. Tan, K. Sim, B. Lewis, W. Mieghem, G. Lip, Jae Kim, Fernando Lanas-Zanetti, A. González-Hermosillo, A. Dans, M. Munawar, M. O’Donnell, J. Lawrence, G. Lewis, Rizwan Afzal, S. Yusuf (2011)
Apixaban in patients with atrial fibrillation.The New England journal of medicine, 364 9
G. Albers, D. Sherman, D. Gress, J. Paulseth, P. Petersen (1991)
Stroke prevention in nonvalvular atrial fibrillation: A review of prospective randomized trialsAnnals of Neurology, 30
J. Heeringa, D. Kuip, A. Hofman, J. Kors, G. Herpen, B. Stricker, T. Stijnen, G. Lip, J. Witteman (2006)
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.European heart journal, 27 8
A. Verma, J. Cairns, L. Mitchell, L. Macle, I. Stiell, D. Gladstone, M. Mcmurtry, S. Connolly, J. Cox, P. Dorian, N. Ivers, K. Leblanc, S. Nattel, J. Healey (2014)
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.The Canadian journal of cardiology, 30 10
M. Ezekowitz, S. Connolly, A. Parekh, P. Reilly, Jeanne Varrone, Susan Wang, J. Oldgren, E. Themeles, L. Wallentin, S. Yusuf (2009)
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.American heart journal, 157 5
MW Sherwood, JD Douketis, MR Patel (2014)
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Circulation, 129
R. Pisters, D. Lane, R. Nieuwlaat, C. Vos, H. Crijns, G. Lip (2010)
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.Chest, 138 5
S. Stewart, C. Hart, D. Hole, J. McMurray (2001)
Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley studyHeart, 86
(2015)
The fourth new oral anticoagulant
Guía de práctica clínica (GPC): 3 actualización 2011. Diagnóstico y tratamiento de la fibrilación auricular
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin (2009)
Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 361 12
A. Rayo, Oscar Olazo, G. Hernández, R. Ocaña, Vicente Barrientos, J. Castellanos, Raúl García, Raúl Juárez, F. Mata, Luis Torrecilla, Uriel Nava (2008)
Epidemiología de la enfermedad vascular cerebral en hospitales de la Ciudad de México. Estudio multicéntrico, 24
C. Walraven, Alison Jennings, Natalie Oake, D. Fergusson, A. Forster (2006)
Effect of study setting on anticoagulation control: a systematic review and metaregression.Chest, 129 5
MR Patel, KW Mahaffey, J Garg (2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med, 365
S. Kaatz, C. Mahan (2014)
Stroke Prevention in Patients With Atrial Fibrillation and Renal DysfunctionStroke, 45
K. Mann, K. Brummel, S. Butenas (2003)
What is all that thrombin for?Journal of Thrombosis and Haemostasis, 1
M. Sudlow, R. Thomson, B. Thwaites, H. Rodgers, R. Kenny (1998)
Prevalence of atrial fibrillation and eligibility for anticoagulants in the communityThe Lancet, 352
(2006)
Active Writing Group
C Lafuente-Lafuente, I Mahe, F Extramiana (2009)
Management of atrial fibrillationBMJ 5, 339
B. Gage, A. Waterman, W. Shannon, M. Boechler, M. Rich, M. Radford (2001)
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.JAMA, 285 22
B. Eriksson, D. Quinlan, J. Weitz (2009)
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in DevelopmentClinical Pharmacokinetics, 48
(2012)
apixaban) approved in Europe for prevention of stroke and systemic 12 embolism in patients with nonvalvular atrial fibrillation
D. Siegal, J. Curnutte, S. Connolly, Genmin Lu, P. Conley, B. Wiens, Vandana Mathur, J. Castillo, M. Bronson, J. Leeds, Florie Mar, A. Gold, M. Crowther (2015)
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.The New England journal of medicine, 373 25
(2015)
and Drug Administration
G. Lip, D. Lane (2015)
Stroke prevention in atrial fibrillation: a systematic review.JAMA, 313 19
(2012)
New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function
M. Freedman (1992)
Oral Anticoagulants: Pharmacodynamics, Clinical Indications and Adverse EffectsThe Journal of Clinical Pharmacology, 32
C. Granger, J. Alexander, J. McMurray, R. Lopes, E. Hylek, M. Hanna, H. Al-Khalidi, J. Ansell, D. Atar, Á. Avezum, M. Bahit, R. Diaz, J. Easton, J. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B. Gersh, S. Golitsyn, S. Goto, A. Hermosillo, S. Hohnloser, J. Horowitz, Puneet Mohan, P. Janský, B. Lewis, J. López-Sendón, P. Pais, A. Parkhomenko, F. Verheugt, Jun Zhu, L. Wallentin (2013)
Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trialEuropean Heart Journal, 34
La Situación Demográfica en México 2013 [ online ]
A. Garrett, Pharmd, Bcps (2015)
Idarucizumab for dabigatran reversalFormulary
D. Capodanno, P. Capranzano, G. Giacchi, V. Calvi, C. Tamburino (2013)
Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients.International journal of cardiology, 167 4
R. Hart, L. Pearce, M. Aguilar (2007)
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 146
J. Stangier (2008)
Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 47
W. Baker, O. Phung (2012)
DO DIFFERENCES EXIST BETWEEN ORAL ANTICOAGULANTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION? AN ADJUSTED INDIRECT COMPARISON META-ANALYSISJournal of the American College of Cardiology, 59
Claude Hemphill, Steven Greenberg, C. Anderson, Kyra Becker, B. Bendok, Mary Cushman, Gordon Fung, J. Goldstein, R. Macdonald, Pamela Mitchell, Phillip Scott, M. Selim, Daniel Woo (2015)
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationStroke, 46
Jørgensen Hs, H. Nakayama, J. Reith, H. Raaschou, T. Olsen (1996)
Acute stroke with atrial fibrillation. The Copenhagen Stroke Study.Stroke, 27 10
K. Bauer (2012)
Reversal of antithrombotic agentsAmerican Journal of Hematology, 87
A. Go, E. Hylek, Katherine Phillips, Yuchiao Chang, Lori Henault, Joeseph Selby, Daniel Singer (2001)
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.JAMA, 285 18
(2015)
Eliquis (apixaban) 2.5 mg and 5 mg film-coated tablets 17 prescribing information
Carlos Cantú-Brito, J. Ruiz-Sandoval, Luis Murillo-Bonilla, E. Chiquete, Carolina León-Jiménez, A. Arauz, J. Villarreal-Careaga, R. Rangel-guerra, Alma Ramos-Moreno, F. Barinagarrementeria, Premier Investigators (2010)
Manejo agudo y pronóstico a un año en pacientes mexicanos con un primer infarto cerebral: resultados del estudio multicéntrico PREMIERRevista De Neurologia, 51
CB Granger, JH Alexander, JJV McMurray (2011)
Apixaban versus warfarin in patients with atrial fibrillationN Engl J Med, 365
Y. Mo, Felix Yam (2015)
Recent Advances in the Development of Specific Antidotes for Target‐Specific Oral AnticoagulantsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 35
M. Hoffman, D. Monroe (2007)
Coagulation 2006: a modern view of hemostasis.Hematology/oncology clinics of North America, 21 1
(2010)
Acute care and 30 on-year outcome of Mexican patients with first-ever acute ischemic stroke: the PREMIER 31 study
C. January, L. Wann, J. Alpert, H. Calkins, J. Cigarroa, J. Cleveland, J. Conti, P. Ellinor, M. Ezekowitz, M. Field, K. Murray, R. Sacco, W. Stevenson, P. Tchou, C. Tracy, C. Yancy (2014)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.Journal of the American College of Cardiology, 64 21
S. Pearson, R. Troughton, A. Richards (2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.The New England journal of medicine, 365 24
NE Schwartz, GW Albers (2010)
Dabigatran challenges warfarin’s superiority for stroke prevention in atrial fibrillationStroke, 41
Luca Testa, M. Agnifili, Roberto Latini, Roberto Mattioli, S. Lanotte, F. Marco, Jacopo Oreglia, A. Latib, S. Pizzocri, M. Laudisa, N. Brambilla, F. Bedogni (2012)
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.QJM : monthly journal of the Association of Physicians, 105 10
A. Spyropoulos (2007)
Investigational treatments of venous thromboembolismExpert Opinion on Investigational Drugs, 16
J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, G. Palareti (2008)
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest, 133 6 Suppl
N. Schwartz, G. Albers (2010)
Emerging Therapies
Guía de práctica clínica: prevención secundaria en el tratamiento con anticoagulante oral: warfarina en adultos en el preimer nivel de atención médica
R. Hart, H. Diener, Sean Yang, S. Connolly, L. Wallentin, P. Reilly, M. Ezekowitz, S. Yusuf (2012)
Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY TrialStroke, 43
Xarelto Mexican prescribing information
J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, E. Hylek (2004)
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest, 126 3 Suppl
(2015)
el registro de nuevo anticoagulante [Mexican media release dated 27 June 2011
S. Stewart, N. Murphy, A. Walker, A. Mcguire, J. McMurray (2004)
Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UKHeart, 90
Accessed 12
S. Connolly, J. Pogue, R. Hart, M. Pfeffer, S. Hohnloser, S. Chrolavicius, S. Yusuf (2006)
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialThe Lancet, 367
C. January, L. Wann, Joseph Alpert, H. Calkins, Joaquin Cigarroa, Joseph Cleveland, Jamie Conti, P. Ellinor, M. Ezekowitz, Michael Field, Katherine Murray, Ralph Sacco, William Stevenson, Patrick Tchou, C. Tracy, C. Yancy (2014)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Circulation, 130 23
R. Giugliano, C. Ruff, E. Braunwald, S. Murphy, S. Wiviott, J. Halperin, A. Waldo, M. Ezekowitz, J. Weitz, J. Špinar, W. Rużyłło, M. Ruda, Y. Koretsune, Joshua Betcher, M. Shi, L. Grip, Shirali Patel, Indravadan Patel, J. Hanyok, M. Mercuri, E. Antman (2013)
Edoxaban versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 369 22
S. Connolly, J. Pogue, R. Hart, S. Hohnloser, M. Pfeffer, S. Chrolavicius, S. Yusuf (2009)
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.The New England journal of medicine, 360 20
M. Kamalesh, A. Cerel, A. Burger (1992)
Management of atrial fibrillation.The New England journal of medicine, 327 14
G. Lip, T. Larsen, F. Skjøth, L. Rasmussen (2012)
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.Journal of the American College of Cardiology, 60 8
L. Wallentin, S. Yusuf, M. Ezekowitz, M. Alings, M. Flather, M. Franzosi, P. Pais, A. Dans, J. Eikelboom, J. Oldgren, J. Pogue, P. Reilly, Sean Yang, S. Connolly (2010)
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialThe Lancet, 376
A. Camm, P. Kirchhof, G. Lip, U. Schotten, I. Savelieva, S. Ernst, I. Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. Caterina, J. Sutter, A. Goette, B. Gorenek, M. Heldal, Stefan Hohloser, P. Kolh, J. Heuzey, P. Ponikowski, F. Rutten, A. Vahanian, A. Auricchio, Jeroen Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, Richard Hobbs, P. Kearney, T. McDonagh, B. Popescu, Željko Reiner, U. Sechtem, P. Sirnes, M. Tendera, P. Vardas, Petr Widimsky, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlöf, T. Folliguet, M. Glikson, M. Goethals, D. Gulba, S. Ho, R. Klautz, S. Kose, John Mcmurray, P. Filardi, P. Raatikainen, M. Salvador, M. Schalij, A. Shpektor, J. Sousa, J. Stȩpińska, H. Uuetoa, J. Zamorano, I. Zupan (2010)
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 12 10
(2015)
Xarelto Prescribing Information [online]. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0
Stefan Hohnloser, G. Hindricks, S. Kristensen, Frans Rutten (2012)
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 14 10
L. Wilkins (1991)
Stroke Prevention in Atrial Fibrillation Study: Final ResultsCirculation, 84
G. Lip, R. Nieuwlaat, R. Pisters, D. Lane, H. Crijns (2010)
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.Chest, 137 2
(2008)
Physicians Evidence - Based Clinical Practice Guidelines ( 8 th Edition )
R. Lopes, S. Al‐Khatib, L. Wallentin, Hongqiu Yang, J. Ansell, M. Bahit, R. Caterina, P. Dorian, J. Easton, Ç. Erol, J. Ezekowitz, B. Gersh, C. Granger, S. Hohnloser, J. Horowitz, E. Hylek, J. McMurray, Puneet Mohan, D. Vinereanu, J. Alexander (2012)
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trialThe Lancet, 380
D. Budnitz, M. Lovegrove, Nadine Shehab, C. Richards (2011)
Emergency hospitalizations for adverse drug events in older Americans.The New England journal of medicine, 365 21
V. Fuster, L. Rydén, Davis Cannom, H. Crijns, A. Curtis, K. Ellenbogen, J. Halperin, J. Heuzey, G. Kay, J. Lowe, S. Olsson, E. Prystowsky, J. Tamargo, S. Wann, Sidney Smith, A. Jacobs, C. Adams, Jeffery Anderson, E. Antman, S. Hunt, Rick Nishimura, J. Ornato, R. Page, B. Riegel, S. Priori, J. Blanc, A. Budaj, A. Camm, V. Dean, J. Deckers, Catherine Despres, K. Dickstein, J. Lekakis, K. Mcgregor, M. Metra, J. Morais, A. Osterspey, J. Zamorano (2006)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing CommitJournal of the American College of Cardiology, 48 4
Atrial fibrillation (AF) is associated with an increased risk of stroke. AF-related strokes cause greater disability and mortality than those in patients without AF, and are associated with a significant clinical and economic burden in Mexico. Antithrombotic therapy reduces stroke risk in patients with AF and is recommended for all patients except those classified as having a low stroke risk. However, its use is suboptimal all around the world; one study showed that only 4 % of Mexican patients with AF who presented with ischemic stroke were in the therapeutic range for anticoagulation. Vitamin K antagonists (VKAs) such as warfarin or acenocoumarin have long been the only oral anticoagulants for stroke prevention in AF. Although effective, VKAs have disadvantages, including the need for regular coagulation monitoring and dose adjustment. Interactions with numerous common medications and foods contribute to the risk of serious bleeding and thrombotic events in VKA-treated patients. Thus novel oral anticoagulants (NOACs), more properly called direct oral anticoagulants (DOACs), such as dabigatran etexilate, rivaroxaban, apixaban, and edoxaban (not available in Mexico), have been developed. These offer the convenience of fixed-dose treatment without the need for monitoring, and have few drug or food interactions. Pivotal phase III trials have demonstrated that these agents are at least as effective as warfarin in preventing stroke and are associated with a reduced risk of intracranial hemorrhage. With apixaban approved in Mexico in April 2013, clinicians now have the choice of three novel DOACs as alternatives to warfarin. However, it is yet to be established which of these agents should be the first choice, and treatment decisions are likely to depend on the individual patient’s characteristics.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Feb 29, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.